Regression of atherosclerosis and related CV diseases
|
|
- Valerie Hall
- 5 years ago
- Views:
Transcription
1 Regression of atherosclerosis and related CV diseases Jean-Claude Tardif MD, FRCPC, FACC, FCAHS Director, MHI Research Center Professor of Medicine UdeM Endowed Research Chair in Atherosclerosis Montreal Heart Institute Université de Montréal
2 Change in atheroma volume in 6 weeks in statin-naïve patients Relative change Nominal change ± Adjusted mean ± SE P =.2 Chronic statin therapy prior to ACS (n = 38) ±.96 Newly initiated statin therapy following ACS (n = 36) Median (IQR) P =.3 Chronic statin therapy prior to ACS (n = 38) -9.1 Newly initiated statin therapy following ACS (n = 36) Rodes J and Tardif JC, Am J Cardiol 29;14:75-7
3 Substantial Risk of CHD Events Remains for Many Patients on Statin Therapy Trial (N) WOSCOPS b (6595) AFCAPS/TexCAPS b (665) ASCOT-LLA b (1,35) 4S b (4444) CARE c (4159) LIPID c (914) HPS c (2,536) PROSPER c (584) Statin treatment Pravastatin 4 mg Lovastatin 2 or 4 mg Atorvastatin 1 mg Simvastatin 2 mg Pravastatin 4 mg Pravastatin 4 mg Simvastatin 4 mg Pravastatin 4 mg Risk reduction vs placebo 31% 37% 36% 26% 24% 24% 27% 19% Clinical events a Remaining risk 69% 63% 64% 74% 76% 76% 73% 81% a Nonfatal myocardial infarction and coronary heart death; b Primary prevention trial; c Secondary prevention trial WOSCOPS=West of Scotland Coronary Prevention Study; AFCAPS/TexCAPS=Air Force/Texas Coronary Atherosclerosis Prevention Study; ASCOT-LLA=Anglo- Scandinavian Cardiac Outcomes Trial Lipid Lowering Arm; 4S=Scandinavian Simvastatin Survival Study; CARE=Cholesterol and Recurrent Events; LIPID=Long-Term Intervention with Pravastatin in Ischemic Disease; HPS=Heart Protection Study; PROSPER=Prospective Study of Pravastatin in the Elderly at Risk Adapted from Mahley RW, Bersot TP. In: Goodman & Gilman s The Pharmacological Basis of Therapeutics. 11th ed. New York: McGraw-Hill Medical Publishing Division, 26: ; Bays HE. Expert Rev Cardiovasc Ther. 24;2:485 51; Shepherd J et al. N Engl J Med. 1995;333: ; Downs JR et al. JAMA. 1998;279: ; Sever PS et al. Lancet. 23;361: ; Scandinavian Simvastatin Survival Study Group. Lancet. 1994;344: ; Sacks FM et al. N Engl J Med. 1996;335:11 19; Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Eng J Med. 1998;339: ; Heart Protection Study Collaborative Group. Lancet. 22;36:7 22; Shepherd J et al. Lancet. 22;36:
4 Risk of death according to presence of metabolic syndrome Survival (all-cause) Survival (CV) 1. p <.1 p < No WHO metabolic syndrome WHO metabolic syndrome Time (years) No at risk No MS MS Time (years) No WHO metabolic syndrome WHO metabolic syndrome Nigam A, Bourassa MG, Fortier A, Guertin MC, Tardif JC. Am Heart J 26; 151:
5 Lipoprotein metabolism Liver LDL receptor ACAT MTP FC CE 27-hydroxylase ApoB ABCG1 B E VLDL C-II LPL B E IDL C-II LPL LDL B Oxidation CD36 SR-A FC CE ACAT Bile Intestine FC CE ACAT IBAT CETP A-1 A-1 LCAT HDL PL TP HL Nascent HDL Cholesterol pool ABC1 Macrophage
6 Change in plaque volume A+ 3-mm segment, intent-to-treat population mm ± 3. 4 p =.58 (unadjusted) p =.17 (adjusted) Mean change (±SD) ± ± ± 26.6 Placebo (n=19) Avasimibe Avasimibe Avasimibe 5 mg 25 mg 75 mg (n = 18) (n = 98) (n = 117) Tardif et al Circulation 24; 11:3372-7
7 Long-Term Safety of Intravascular Ultrasound A+ Coronary change score 2 New lesions Disease progression (mm) p =.35 (% of patients) p =.84* p =.27* -.1 Instrumented (IVUS-related arteries) Non-instrumented (Non-IVUS arteries) J Am Coll Cardiol 25;45:
8 IVUS assessment - Atherosclerosis regression 2% reduction in plaque burden Baseline Follow-up Plaque volume (mm 3 ): EEM volume (mm 3 ): 69.5 Plaque volume (mm 3 ): EEM volume (mm 3 ): 445.9
9 6 4 2 Correlations between changes in plaque, vessel and lumen areas in pts with regression Mean vessel area (mm 2 ) n = 227 r =.64 p <.1 Mean lumen area (mm 2 ) n = 227 r =.2 p = Change in mean plaque area (mm 2 ) Change in mean plaque area (mm 2 ) Tardif et al. Am J Cardiol 26;
10 IVUS results in patients with angiographic progression vs no progression by QCA in the IVUS-related artery Mean plaque volume (mm 3 ) Progression No progression ± 72.1 p = ± ± 69.9 p = ± Baseline Follow-up P-value for mean change in plaque volume:.283 Circulation 27;115:1851-7
11 Prognostic significance of angiographic progression of coronary atherosclerosis 1. Any coronary event ( n = 112) 1. Death or MI (n = 4) Non progressors Proportion event free Non progressors Progressors Months Proportion event free.75 p <.1 p < Progressors (N = 26) (N = 137) (N = ) (N = ) (N = 39) (N = 192) (N = 5) (N = 1) Months Circulation 1993; 87:
12 Canadian Atherosclerosis Imaging Network Clinical Translation and Practice Correlation of coronary and carotid atherosclerosis and their changes over time and links with clinical outcomes 2 patients undergoing coronary angiography, IVUS (with virtual histology) and carotid ultrasound (IMT and plaques) at baseline and 24 months 5-year follow-up for cardio/cerebrovascular events NIRS, PET/CT, MRI and microvascular substudies Genomic (including mirnas) and biomarker biobanks Proteomic and metabolomic analyses Application of this knowledge and framework in clinical trials of novel anti-atherosclerotic agents
13 Beyond statin-induced LDL-C reduction CETP inhibitors HDL infusions/mimetics 5-LO/FLAP inhibitors PLA2 inhibitors Serpins Heart rate reduction? Tardif JC, Heinonen T. Nature Clin Pract CV Med 26;3:366-7
14 INHIBITION OF ATHEROSCLEROSIS BY HDL Monocyte HDL INHIBITS ADHESION MOLECULE EXPRESSION HDL INHIBITS MCP-1 1 EXPRESSION LDL Adhesion Molecule Cytokines MCP-1 LDL MODIFIED LDL HDL INHIBITS OXIDATION OF LDL Macrophage HDL PROMOTES CHOLESTEROL EFFLUX Foam Cell
15 Effects of rapo-a1 Milano on coronary atherosclerosis Change in atheroma volume 1 Change in % atheroma volume -4-8 mm 3 % ± 23.3 Placebo (n = 11) ± mg/kg (n = 21) ± mg/kg (n = 15) ETC ± 39.5 p =.97 p =.2 p =.7 p <.1 Combined (n = 36) ± 3.9 Placebo (n = 11) ± mg/kg (n = 21) -.73 ± mg/kg (n = 15) ETC ± 3.17 p =.3 p =.45 p =.2 Combined (n = 36) JAMA 23; 29:
16 Change in atheroma volume on IVUS Median percent change The ERASE trial Median nominal change p=ns p =.7 % mm p=ns P= p <.1 CSL-111 (n = 89) Placebo (n = 47) Plaque volume at baseline: 146. mm 3 for CSL-111, mm 3 for placebo Interval between IVUS examinations : 43 ± 6 days in both groups p <.1 CSL-111 (n = 89) Placebo (n = 47) Tardif et al. JAMA 27;297:
17 The ERASE trial Changes in plaque characterization indexes.2 Arc index.2 Inner perimeter index Least square means Least square means p =.1 p = CSL-111 Placebo -.2 CSL-111 Placebo Tardif et al. JAMA 27;297:
18 The ERASE trial Changes in coronary score on QCA Least square means (mm) There was a significant interaction between study treatment and baseline coronary score (p =.3) 1.76 mm 1st quartile CSL mg/kg 2. mm Median Placebo p = mm 3rd quartile Coronary score at baseline JAMA 27;297:
19 Lipoprotein metabolism Liver LDL receptor ACAT MTP FC CE 27-hydroxylase ApoB ABCG1 B E VLDL C-II LPL B E IDL C-II LPL LDL B Oxidation CD36 SR-A FC CE ACAT Bile Intestine FC CE ACAT IBAT CETP A-1 A-1 LCAT HDL PL TP HL Nascent HDL Cholesterol pool ABC1 Macrophage
20 ILLUSTRATE Primary endpoint Change in Percent Atheroma Volume,35,3 p =.72 Change in percent atheroma volume,25,2,15,19,12,1,5 *LS Mean change p value from ANCOVA Atorvastatin monotherapy Torcetrapibatorvastatin Nissen, Tardif, et al. N Engl J Med 27; 356:134-16
21 ILLUMINATE - Primary Endpoint Time to First MCVE*: Kaplan-Meier Plot Event Free (%) Atorvastatin (A) events = 373 Hazard Ratio 1.25 P=.1 9 Torcetrapib/Atorvastatin (T/A) events = Days from Randomization *Major cardiovascular event: CHD death, non-fatal MI, stroke or hospitalization for unstable angina NEJM 27;357:
22 Post-hoc Exploratory Analyses in the Torcetrapib/Atorvastatin Group CHD Death or Non-Fatal MI (Hazard Ratio) Hazard ratios for CHD Death or Non-Fatal MI by quintile of on-trial HDL-C (referent group is HDL-C C < 6 mg/dl stratum) < >93 Quintiles of HDL-C C (mg/dl) at Month 3 *P<.5 Cox proportional hazard model adjusted for age, gender and baseline HDL-C. Excludes 265 patients with missing month 3 HDL-C. Preliminary analysis initiated and authorised by P Barter and d conducted by Pfizer * * *
23 Lack of Effect of Dalcetrapib vs Torcetrapib on Aldosterone Secretion 7 6 RO Torcetrapib Aldosterone fmole/µg protein ,1,5,1,25,1 1 2,5 5 7,5 1 AngII 1 nm Concentration of Torcetrapib or RO (µm)
24 The dal-heart Program dalcetrapib HDL Evaluation, Atherosclerosis & Reverse cholesterol Transport The dal-heart Program tests a novel hypothesis: enhancing HDL efficacy through CETP modulation treats the underlying disease of atherosclerosis and will attenuate CV risk dal- OUTCOMES 1 15,6 patients recently hospitalized for ACS To evaluate the effect of dalcetrapib on CV outcomes RECRUITMENT COMPLETE dal-vessel 2 45 patients with CHD or CHD risk equivalent To evaluate the effect of dalcetrapib on endothelial function and blood pressure, measured by FMD and ABPM RECRUITMENT COMPLETE dal-plaque 3 13 patients with CHD To evaluate the effect of dalcetrapib on inflammation, plaque size and burden, measured by PET/CT and MRI RECRUITMENT COMPLETE dal-plaque patients with CAD To evaluate the effect of dalcetrapib on atherosclerotic disease progression, assessed by IVUS and carotid B-mode ultrasound RECRUITING 1 Schwartz et al. Am Heart J 29;158:896-91; 2 Accessed April 1st 21; 3 Accessed April 1st 21; 4 Accessed April 1st 21.
25 DAL-OUTCOMES Study Design A double-blind, randomized, placebo-controlled, parallel group, multi-centre study in 15,6 patients recently hospitalized for ACS Double-blind Single-blind Placebo Run-in 4-12 Weeks Dalcetrapib 6 mg Placebo Until 16 events occur but at least a minimum of 2 years Visit 1 Visit 2 Visit 3 randomization 1 : 1 Follow up 1 st year: every 3 months Following years: every 4 months
26 dal-plaque-2: Study Design Objective: to assess the effect of dalcetrapib versus placebo on atherosclerotic disease progression in patients with CAD A double-blind, randomized, placebo-controlled, parallel-group multicenter study in 9 patients with CAD Double-blind Pre-rando phase Screening phase up to 8 weeks Baseline IVUS, QCA and CIMT Randomization dalcetrapib 6 mg placebo Background of contemporary evidence-based therapy for CAD and CV risk factors Primary endpoints: IVUS and CIMT at 24 months Other assessments: CIMT at 6+12 months; QCA at 24 months 24 months
27 dal-plaque-2 Primary endpoints Co-primary endpoints Nominal change from baseline to study end in coronary percent atheroma volume (PAV) for all anatomically comparable slices in a 3-mm segment of the target coronary artery assessed by IVUS Rate of change from baseline to study end in intima-media thickness (IMT), defined as the per scan average of the far wall MEAN IMT values of the right and left common carotid, carotid bulb and internal carotid arterial segments as assessed by carotid B-mode ultrasound
28 British Journal of Pharmacology 28; 154:
29 Aortic valve area during treatment Aortic valve area (mm 2 ) Control Treated ** * * *p<.5 **p<.1 Days Stop cholesterol diet + Vit D 2 Start ApoA-I mimetic peptide treatment Br J Pharmacol 28;154:
30 The dual PPAR agonist aleglitazar and change in HDL-C 35 Placebo Pioglitazone 3 p<.1 p<.1 p<.1 % BL of HDL - C p=.312 p< n BC2214 Investigator Meeting
31 Aleglitazar 15 μg Provides Beneficial Effects on Cardiovascular Biomarkers 2 Placebo Aleglitazar 15 µg Pioglitazone 45 mg Mean Absolute Change From Baseline ,1-35, ,1-1,6-1, ,7-5 -7,3 Fibrinogen (mg/dl) hscrp (mg/dl) PAI-1 (µg/ml) Placebo Aleglitazar 15 µg Pioglitazone 45 mg Fibrinogen baseline (mg/dl) hscrp baseline (mg/dl) PAI-1 baseline (µg/ml)
32 ALECARDIO Study Design Run-in Period 2 6 (+ 6) weeks Treatment Period at least 2.5 years 4 weeks Index ACS Event Screened Patients Aleglitazar 15 µg Placebo Follow-up Standard of care (diabetes and other CV risk factors) BC2214 Investigator Meeting
33 Potential therapeutic targets in CV diseases
34 VIA-2291 Decreases ex Vivo Whole Blood LTB4 Production from Baseline through Week 12 Mean LTB4 Production [pg/ml] 16,. 14,. 12,. 1,. 8,. 6,. 4,. 2, Error Bars represent 95% CI ** p <.1 ANCOVA Change from Baseline Placebo 25mg 5mg 1mg Study Weeks ** ** Tardif et al. Circulation Cardiovasc Imaging 21;3: **
35 Significant Decrease in hs-crp in VIA mg Group versus Placebo at 24 Weeks
36 Change in non-calcified plaque volume and patients with new plaque lesions on serial coronary CT scans in the VIA-2291 groups versus placebo at 24 Weeks Plaque volume (mm 3 ) Pts with new plaques (%) p <.1 p < Placebo All VIA-2291 Placebo All VIA-2291 Tardif et al. Circulation Cardiovasc Imaging 21;3:298-37
37 Serp-1 Phase 2a Results: Myocardial Enzymes TroponinI:Adjusted Geometric Mean CK-MB: Adjusted Geometric Mean Troponin I (ng/ml) Placebo 5 µg/kg Dose 15 µg/kg Dose CK-MB (ng/ml) Placebo 5 µg/kg Dose 15 µg/kg Dose Predose 8 hr 16 hr 24 hr 48 hr 54 hr Day 14 Day 28 1 Predose 8 hr 16 hr 24 hr 48 hr 54 hr Day 14 Day 28 VT VT VT VT VT VT =statistically significant (p<.5 vs control) VT = timing of doses Dose-dependent reduction in biomarkers of cardiac damage observed in the first 24 hours Tardif et al. Circulation Cardiovasc Interventions 21 (in press) 37
38 1..9 Mortality by resting heart rate Overall mortality 1..9 CV mortality Cumulative survival RHR in quintiles 62 bpm 63-7 bpm bpm bpm 83 bpm Years after enrolment Years after enrolment Adjusted for age, gender, hypertension, diabetes, smoking, NDCV, ejection fraction, recreational activity, medications including β-blockers, plus BMI for CV mortality Diaz A, Bourassa MG, Guertin MC, Tardif JC. Eur Heart J 25; 26:
39 Ivabradine prevents endothelial dysfunction associated with dyslipidemia in mice Dilation (% of maximal dilation) Wild WT type Dyslipidemia DL DL+Ivabradine + IVA RENAL * * # Dilation (% of maximal dilation) Wild WT type Dyslipidemia DL DL+Ivabradine + IVA CEREBRAL # ACh (µm) ACh (µm) E max : P <.5 vs. to WT; # P <.5 vs. to DL pd 2 : * P <.5 vs. WT and DL Drouin et al. Br J Pharmacol. 28;154:
40 TED at trough of drug activity n Ivabradine vs atenolol Favors ATE Favors IVA INITIATIVE E (95% CI) P for non inferiority IVA 5 mg bid vs ATE 5 mg od at M (-7.4; 2.8) p <.1 IVA 7.5 mg bid vs ATE 1 mg od at M (-8.3; 28.8) p <.1 IVA 1 mg bid vs ATE 1 mg od at M (-2.9; 34.3) 286 p <.1-35 sec + 35 sec Equivalence interval Tardif JC et al. Eur Heart J 25; 26:
41 Ivabradine increases all ETT parameters in patients already receiving beta-blockers 889 stable angina patients, 2 countries 6 Ivabradine + atenolol Placebo + atenolol P<.1 P<.1 Change in ETT criteria* (s) at 4 months P<.1 P<.1 1 Total exercise duration Time to limiting angina Time to angina onset Time to 1mm ST segment depression *Evaluated at trough of drug activity Tardif JC, et al. Eur Heart J. 29;3:
42 Effect of Ivabradine on hospitalisation for fatal and non-fatal MI (HR 7 bpm) % with hospitalisation for fatal and non-fatal MI Hazard ratio =.64 (.49.84) RR = -36% P =.1 Placebo 2 Ivabradine Years Lancet Online August 31, 28.
43 Primary composite endpoint (CV death or hospital admission for worsening HF) 43 Cumulative frequency (%) 4 3 HR =.82 (.75.9) P <.1 Placebo 18% 2 Ivabradine Swedberg K, et al. Lancet. 21;online August 29. Months
44 Population Outpatients with stable CAD without LVSD (EF > 4%) or clinical signs of HF, with appropriate CV medication Ivabradine Starting dose 7.5 mg bid Run in 2-4 weeks Target HR: 55-6 bpm Placebo bid M M3 M6 Every 6 months Methods Events: 4.5% per year in the placebo group 17 primary composite endpoints (cardiovascular death and non fatal MI N = 11 33, mean follow up = 2.5 years; RRR = 18%, α bilateral 5%, power 9%
45 Canadian Atherosclerosis Imaging Network Hearts and Minds Stems from CIHR s 27 consensus conference on imaging Five-year (28-213) 1M$ operating grant from CIHR Infrastructure grant 25M$ from CFI in June 29 Unique network combining in vivo imaging of vessel wall disease, endorgan disease, clinical and pathological endpoints Enables cross-sectional and longitudinal clinical studies of coronary, carotid and peripheral vascular beds International resource for studying the natural history of atherosclerosis and novel therapeutic interventions
46 Canadian Atherosclerosis Imaging Network CAIN one imaging network for one entire country Imaging Core Analysis Laboratories (vascular) IVUS, 3-D US, QCA, MDCT, MRI, PET/CT, SPECT Imaging Core Analysis Laboratories (end-organ) Pan-canadian network of 45 partner sites Data coordinating and image repository center (MHICC) Genetic, pharmacogenomic and biomarker biobanks Proteomic and metabolomic analyses Tissue samples
47 CAIN Research themes Hearts and Minds Vascular biology of atherosclerotic plaque Vascular imaging technology development and assessment Translation to clinical research and clinical practice
48 Canadian Atherosclerosis Imaging Network 1- Vascular Biology of Atherosclerotic Plaque Assess natural history of the plaque from 3 time points (MRI): Plaque initiation, progression and complication Evaluate inflammation, neovascularization and hemorrhage Determine the role of stimuli such as Db and hyperlipidemia Study the genetics of atheroma Assess the role of hypertension, hemodynamics and the interaction with blood constituents at the site of plaque rupture
49 Canadian Atherosclerosis Imaging Network 2- Vascular Imaging Technology Development and Assessment Validation of developing technologies through quantitative histological examination of surgical specimens Includes: Carotid ultrasound - surface morphology, plaque vulnerability and plaque volume 18FDG-PET metabolic activity and inflammation Ultrasound microbubbles plaque neovascularity
50 Canadian Atherosclerosis Imaging Network 3- Translation to Clinical Research/Practice Correlation of coronary and carotid atherosclerosis and their changes over time and links with clinical outcomes 2 patients undergoing coronary angiography, IVUS (with virtual histology) and carotid ultrasound (IMT and plaques) at baseline and 24 months 5-year follow-up for cardio/cerebrovascular events NIRS, PET/CT, MRI and microvascular substudies Genomic (including mirnas) and biomarker biobanks Proteomic and metabolomic analyses Application of this knowledge and framework in clinical trials of novel anti-atherosclerotic agents
51 Canadian Atherosclerosis Imaging Network CAIN one imaging network for one entire country
52 52
CETP inhibition: pros and cons. Philip Barter The Heart Research Institute Sydney, Australia
CETP inhibition: pros and cons Philip Barter The Heart Research Institute Sydney, Australia Philip Barter Disclosures Received honorariums for lectures, consultancies or membership of advisory boards from:
More informationThe inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema
The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema Dept Cardiology, Leiden University Medical Center, Leiden,
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationData Alert. Vascular Biology Working Group. Blunting the atherosclerotic process in patients with coronary artery disease.
1994--4 Vascular Biology Working Group www.vbwg.org c/o Medical Education Consultants, LLC 25 Sylvan Road South, Westport, CT 688 Chairman: Carl J. Pepine, MD Eminent Scholar American Heart Association
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationLipid Lowering in Patients at High Risk for Cardiovascular Disease
Lipid Lowering in Patients at High Risk for Cardiovascular Disease Prof. John J.P. Kastelein, MD PhD FESC Dept. of Vascular Medicine Academic Medical Center / University of Amsterdam The Netherlands Novel
More informationImaging Biomarkers: utilisation for the purposes of registration. EMEA-EFPIA Workshop on Biomarkers 15 December 2006
Imaging Biomarkers: utilisation for the purposes of registration EMEA-EFPIA Workshop on Biomarkers 15 December 2006 Vascular Imaging Technologies Carotid Ultrasound-IMT IVUS-PAV QCA-% stenosis 2 ICH E
More informationRikshospitalet, University of Oslo
Rikshospitalet, University of Oslo Preventing heart failure by preventing coronary artery disease progression European Society of Cardiology Dyslipidemia 29.08.2010 Objectives The trends in cardiovascular
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationHow to Reduce Residual Risk in Primary Prevention
How to Reduce Residual Risk in Primary Prevention Helene Glassberg, MD Assistant Professor of Medicine Section of Cardiology Hospital of the University of Pennsylvania Philadelphia, PA USA Patients with
More informationNovel HDL Targeted Therapies: The Search Continues Assoc. Prof. K.Kostner,, Univ. of Qld, Brisbane
Novel HDL Targeted Therapies: The Search Continues Assoc. Prof. K.Kostner,, Univ. of Qld, Brisbane Kostner, 2007 2008 LDL Target depends on your level of Risk Acute Plaque Rupture ACS (UA/NSTEMI/STEMI)
More informationAtherosclerosis Regression An Overview of Recent Findings & Issues
Atherosclerosis Regression An Overview of Recent Findings & Issues 13th Angioplasty Summit 2008 Cheol Whan Lee, MD University of Ulsan, Asan Medical Center, Seoul, Korea CardioVascular Research Foundation
More informationSpotty Calcification as a Marker of Accelerated Progression of Coronary Atherosclerosis : Insights from Serial Intravascular Ultrasound
Spotty Calcification as a Marker of Accelerated Progression of Coronary Atherosclerosis : Insights from Serial Intravascular Ultrasound Department of Cardiovascular Medicine Heart and Vascular Institute
More informationAPPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES
APPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES Main systematic reviews secondary studies on the general effectiveness of statins in secondary cardiovascular prevention (search date: 2003-2006) NICE.
More informationCottrell Memorial Lecture. Has Reversing Atherosclerosis Become the New Gold Standard in the Treatment of Cardiovascular Disease?
Cottrell Memorial Lecture Has Reversing Atherosclerosis Become the New Gold Standard in the Treatment of Cardiovascular Disease? Stephen Nicholls MBBS PhD @SAHMRI_Heart Disclosures Research support: AstraZeneca,
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationLipid/Lipoprotein Structure and Metabolism (Overview)
Lipid/Lipoprotein Structure and Metabolism (Overview) Philip Barter President, International Atherosclerosis Society Centre for Vascular Research University of New South Wales Sydney, Australia Disclosures
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationLDL cholesterol and cardiovascular outcomes?
LDL cholesterol and cardiovascular outcomes? Prof Kausik Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary
More informationCholesteryl ester transfer protein inhibitors - what have we learnt? Philip Barter The Heart Research Institute Sydney, Australia
Cholesteryl ester transfer protein inhibitors - what have we learnt? Philip Barter The Heart Research Institute Sydney, Australia Philip Barter Disclosures Received honorariums for lectures, consultancies
More informationBehind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL
Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Sung-Joon Lee, PhD Division of Food Science Institute of Biomedical Science and Safety Korea University Composition of Lipoproteins:
More informationModern Lipid Management:
Modern Lipid Management: New Drugs, New Targets, New Hope Kirk U. Knowlton, M.D Director of Cardiovascular Research Co Chief of Cardiology Why lower LDL C in those without evidence of CAD (primary prevention)
More informationLessons from Recent Atherosclerosis Trials
Lessons from Recent Atherosclerosis Trials Han, Ki Hoon MD PhD Asan Medical Center Seoul, Korea Change of concept Primary vs. secondary prevention Low risk vs. High risk High Risk CHD and equivalents CHD
More informationJoslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia
Consensus and Controversy in Diabetes and Dyslipidemia Om P. Ganda MD Director, Lipid Clinic Joslin diabetes Center Boston, MA, USA CVD Outcomes in DM vs non- DM 102 Prospective studies; 698, 782 people,
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationCOURAGE to Leave Diseased Arteries Alone
COURAGE to Leave Diseased Arteries Alone Spencer King MD MACC, FSCAI St. Joseph s s Heart and Vascular Institute Professor of Medicine Emeritus Emory Univ. Atlanta, USA Conflict: I am an Interventionalist
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Cholesterol Treatment Trialists Collaboration.
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More informationESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future
ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future Rory Collins BHF Professor of Medicine & Epidemiology Clinical Trial Service Unit & Epidemiological Studies
More informationIn-Ho Chae. Seoul National University College of Medicine
The Earlier, The Better: Quantum Progress in ACS In-Ho Chae Seoul National University College of Medicine Quantum Leap in Statin Landmark Trials in ACS patients Randomized Controlled Studies of Lipid-Lowering
More informationSubclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD
Subclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD Sao Paulo Medical School Sao Paolo, Brazil Subclinical atherosclerosis in CVD risk: Stratification & management Prof.
More informationLAMIS (Livalo in AMI Study)
JCR 2018. 12. 8 LAMIS (Livalo in AMI Study) Young Joon Hong Division of Cardiology, Chonnam National University Hospital Gwangju, Korea Trend of hypercholesterolemia in Korea < Prevalence of hypercholesterolemia
More informationThe Atherogenic Dyslipidemia of Diabetes Mellitus- Not just a question of LDL-C
The Atherogenic Dyslipidemia of Diabetes Mellitus- Not just a question of LDL-C Eun-Jung Rhee Department of Endocrinology and Metabolism Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationStatins in the elderly : Is there a rationale?
Statins in the elderly : Is there a rationale? Pr B Boland After a communication by Dr. Manfred Gogol EAMA, Sion, June, 2006 1 RCTs with Statins Meta-Analysis, 1999 182 abstracts or research papers 29
More informationShould we treat everybody over 60 years with a statin? Comprehensive primary prevention in practice
Should we treat everybody over 60 years with a statin? Comprehensive primary prevention in practice Pathogenesis of atherosclerosis A decades-long disease course Inflammation Selectins ICAM IL M-CSF CRP
More informationHyperlipidemia: Lowering the Bar on the Lipid Limbo. Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH
Mark slides Hyperlipidemia: Lowering the Bar on the Lipid Limbo Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH Hyperlipidemia is a common problem Nearly 50% of men in the
More informationThere are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?
There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,
More informationInflammation: Novel Target for Cardiovascular Risk Reduction
Inflammation: Novel Target for Cardiovascular Risk Reduction Andrew Zalewski, M.D. Thomas Jefferson University, Philadelphia GlaxoSmithKline, Philadelphia Why inflammation? Population-based studies: low
More informationEnvironmental. Vascular / Tissue. Metabolics
Global Risk Reduction--WINS Picking Mom and Dad-2016 Environmental Vascular / Tissue Metabolics Stop smoking-1b Physical activity-1b Weight control-1b Chelation therapy-3c Influenza vaccination-1b Blood
More informationBest Lipid Treatments
Best Lipid Treatments Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Overview of Talk Review of pathogenesis
More informationPathophysiology of Lipid Disorders
Pathophysiology of Lipid Disorders Henry Ginsberg, M.D. Division of Preventive Medicine and Nutrition CHD in the United States CHD is the single largest killer of men and women 12 million have history
More informationCauses of death in Diabetes
Rates of CV events in Diabetes patients Respiratory4.2 Cancer 7.6 Diabetes 1.3 CV disease 17.3 Causes of death in Diabetes 250 200 150 100 50 0 per 10,000 person-years 97 151 243 Framingham 5 X increase
More informationThe New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk
The New Gold Standard for Lipoprotein Analysis Advanced Testing for Cardiovascular Risk Evolution of Lipoprotein Testing The Lipid Panel Total Cholesterol = VLDL + LDL + HDL Evolution of Lipoprotein Testing
More informationControversies in Lipid Therapy: Is there any value in adjusting HDL levels?
Controversies in Lipid Therapy: Is there any value in adjusting HDL levels? Sergio Fazio, MD, PhD Cornelius Vanderbilt Chair of Cardiovascular Medicine and Professor of Medicine, Pathology, Immunology,
More informationWelcome! Mark May 14, Sat!
Welcome! Mark May 14, Sat! Do We Have All Answers with Statins In Treating Patients with Hyperlipidemia? Kwang Kon Koh, MD, PhD, FACC, FAHA Cardiology, Gil Heart Center, Gachon Medical School, Incheon,
More informationProf. John Chapman, MD, PhD, DSc
Prof. John Chapman, MD, PhD, DSc Director of the Dyslipidemia and Atherosclerosis Research Unit of the National Institute for Health and Medical Research (INSERM) at the Pitié-Salpétrière Hospital in Paris
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationRole of imaging in risk assessment models: the example of CIMT
Role of imaging in risk assessment models: the example of CIMT Diederick E. Grobbee, MD, PhD, FESC Professor of Clinical Epidemiology Julius Center for Health Sciences and Primary Care, University Medical
More informationPCSK9 Inhibitors and Modulators
PCSK9 Inhibitors and Modulators Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Disclosures Speaker s
More informationChanging lipid-lowering guidelines: whom to treat and how low to go
European Heart Journal Supplements (2005) 7 (Supplement A), A12 A19 doi:10.1093/eurheartj/sui003 Changing lipid-lowering guidelines: whom to treat and how low to go C.M. Ballantyne Section of Atherosclerosis,
More information4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
More informationZEUS Trial ezetimibe Ultrasound Study
Trial The lower, The better Is it True for Plaque Regression? Statin alone versus Combination of Ezetimibe and Statin Juntendo University, Department of Cardiology, Tokyo, Japan Katsumi Miyauchi, Naohisa
More informationTreatment of Atherosclerosis in 2007
Treatment of Atherosclerosis in 2007 Szilard Voros, M.D. Medical Director Cardiovascular MR and CT Piedmont Hospital, Piedmont Hospital Our Paradigm Genotype Phenotype Environment Atherosclerotic Disease
More informationSafety of Anacetrapib in Patients with or
Safety of Anacetrapib in Patients with or at Risk for Coronary Heart Disease Christopher P. Cannon, MD, Sukrut Shah, PhD, RPh, Hayes M. Dansky, MD, Michael Davidson, MD, Eliot A. Brinton, MD, Antonio M.
More informationDyslipidaemia. Is there any new information? Dr. A.R.M. Saifuddin Ekram
Dyslipidaemia Is there any new information? Dr. A.R.M. Saifuddin Ekram PhD,FACP,FCPS(Medicine) Professor(c.c.) & Head Department of Medicine Rajshahi Medical College Rajshahi-6000 New features of ATP III
More informationResults of the GLAGOV Trial
Results of the GLAGOV Trial Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound Steven E. Nissen MD Stephen J. Nicholls MBBS PhD Consulting: Many companies
More informationLifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study
Lifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study Harvey White Green Lane Cardiovascular Service and Cardiovascular
More informationDyslipedemia New Guidelines
Dyslipedemia New Guidelines New ACC/AHA Prevention Guidelines on Blood Cholesterol November 12, 2013 Mohammed M Abd El Ghany Professor of Cardiology Cairo Universlty 1 1 0 Cholesterol Management Pharmacotherapy
More informationInflammation and and Heart Heart Disease in Women Inflammation and Heart Disease
Inflammation and Heart Disease in Women Inflammation and Heart Disease What is the link between een inflammation and atherosclerotic disease? What is the role of biomarkers in predicting cardiovascular
More informationManagement of the coronary patient in Roberto Ferrari
Management of the coronary patient in 2011 Roberto Ferrari What is new in treatment of stable CAD? In the era of interventional cardiology, is chronic stable angina a rare disease? Stable angina pectoris
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationClinical Trial Synopsis TL-OPI-516, NCT#
Clinical Trial Synopsis, NCT#00225277 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl Versus
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationDyslipidemia Endothelial dysfunction Free radicals Immunologic
ATHEROSCLEROSIS Hossein Mehrani Professor of Clinical Biochemistry Definition Atherosclerosis: Is a chronic inflammatory process characterized by plaque formation within the vessel wall of arteries and
More informationCoronary artery disease remains the leading
UNMET NEEDS IN THE TREATMENT OF ATHEROSCLEROSIS: WHY ARE WE NOT DONE YET? * Evan A. Stein, MD, PhD ABSTRACT Heart disease remains the leading cause of death in the United States. Despite advances in surgical,
More informationWhat have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?
What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor
More informationEffective Treatment Options With Add-on or Combination Therapy. Christie Ballantyne (USA)
Effective Treatment Options With Add-on or Combination Therapy Christie Ballantyne (USA) Effective treatment options with add-on or combination therapy Christie M. Ballantyne, MD Center for Cardiovascular
More informationEzetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE)
Ezetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE) Thomas Dayspring, MD, FACP Clinical Assistant Professor of Medicine University of Medicine and Dentistry
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationStatin Intolerance. Jason Evanchan DO, FACC April 20 th, 2018
Statin Intolerance 2 nd Annual CV Course for Trainees and Early Career Physicians: Current Concepts in the Diagnosis and Management of Coronary Artery Disease Jason Evanchan DO, FACC April 20 th, 2018
More informationMacrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?
Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists
More informationContributions in Medicine: Will CETP Inhibition Contribute Toward Reduction of Cardiovascular Risk?
Contributions in Medicine: Will TP Inhibition Contribute Toward Reduction of Cardiovascular Risk? Activity presentations are considered intellectual property. These slides may not be published or posted
More informationLandmark Clinical Trials.
Landmark Clinical Trials 1 Learning Objectives Discuss clinical trials and their role in lipid and lipoprotein treatment in cardiovascular prevention. Review the clinical trials of lipid-altering drug
More informationHDL and Arterial Wall
JIFA January 31th 2014 HDL and Arterial Wall P-J TOUBOUL INSERM698 Bichat University Conflict of Interest M Ath intellectual property owner Involvement in R & D for atherosclerosis software developments
More informationThe Cardiovascular Institute Mount Sinai School of Medicine, New York
The Cardiovascular Institute Mount Sinai School of Medicine, New York HDL YES HDL NO Juan Jose Badimon, Ph.D Professor of Medicine Director, Atherothrombosis Research Unit The Mount Sinai School of Medicine
More informationSTATINS FOR PAD Long - term prognosis
STATINS FOR PAD Long - term prognosis Prof. Pavel Poredos, MD, PhD Department of Vascular Disease University Medical Centre Ljubljana Slovenia DECLARATION OF CONFLICT OF INTEREST No conflict of interest
More informationCopyright 2017 by Sea Courses Inc.
Diabetes and Lipids Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or
More informationReverse Cholesterol Transport and Atherosclerosis
JCR2014 (2014.12.13@Novotel, Busan, South Korea) Reverse Cholesterol Transport and Atherosclerosis Shizuya Yamashita, MD, PhD, FAHA, FJCC Department of Community Medicine Department ofcardiovascular Medicine
More informationThe PROSPECT Trial. A Natural History Study of Atherosclerosis Using Multimodality Intracoronary Imaging to Prospectively Identify Vulnerable Plaque
The PROSPECT Trial Providing Regional Observations to Study Predictors of Events in the Coronary Tree A Natural History Study of Atherosclerosis Using Multimodality Intracoronary Imaging to Prospectively
More informationUpdate On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID?
Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID? Karen Aspry, MD, MS, ABCL, FACC Assistant Clinical Professor of Medicine Warren Alpert Medical School of Brown
More informationSTABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY. Harvey D White on behalf of The STABILITY Investigators
STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY Harvey D White on behalf of The STABILITY Investigators Lipoprotein- associated Phospholipase A 2 (Lp-PLA 2 ) activity:
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More informationJanet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode Island Cardiology Center
Primary and Secondary Prevention of Coronary Artery Disease: What is the role of non statin drugs (fenofibrates, fish oil, niacin, folate and vitamins)? Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors
Cardiovascular Risk Factors ROB WALKER (Dunedin, New Zealand) Lipid-lowering therapy in patients with chronic kidney disease Date written: January 2005 Final submission: August 2005 Author: Rob Walker
More informationTraitements associés chez l hypertendu: Statines, Aspirine
Traitements associés chez l hypertendu: Statines, Aspirine Pr Jean-Jacques Mourad CHU Avicenne, Université Paris 13, Bobigny DU HTA, Mars 2012 jean-jacques.mourad@avc.aphp.fr Global Mortality 2000: Impact
More informationProspective Natural-History Study of Coronary Atherosclerosis
Introduction Review of literature from April 2010 to present Concentrated on clinical studies Categories: Atherosclerosis, Lipids, Diabetes and CVD Risk Medical Therapy Statins really could there be anything
More informationWeigh the benefit of statin treatment: LDL & Beyond
Weigh the benefit of statin treatment: LDL & Beyond Duk-Woo Park, MD, PhD Heart Institute, University of Ulsan College of Medicine, Asan Medical, Seoul, Korea FOURIER Further cardiovascular OUtcomes Research
More informationMethods. Background and Objectives STRADIVARIUS
STRADIVARIUS Effect of on Progression of Atherosclerosis in Patients with Abdominal Obesity and Coronary Artery Disease Steven E. Nissen MD Stephen J. Nicholls MBBS PhD, Kathy Wolski MPH, Josep Rodés-Cabau
More informationThe 10 th International & 15 th National Congress on Quality Improvement in Clinical Laboratories
The 10 th International & 15 th National Congress on Quality Improvement in Clinical Laboratories Cardiac biomarkers in atherosclerosis Najma Asadi MD-APCP Ross and Colleagues in 1973: Response to Injury
More informationTrials Enrolled subjects Findings Fox et al. 2014, SIGNIFY 1
Appendix 5 (as supplied by the authors): Published trials on the effect of ivabradine on outcomes including mortality in patients with different cardiovascular diseases Trials Enrolled subjects Findings
More informationDECLARATION OF CONFLICT OF INTEREST. Nothing to disclose
DECLARATION OF CONFLICT OF INTEREST Nothing to disclose Four-Year Clinical Outcomes of the OLIVUS (Impact of OLmesartan on progression of coronary atherosclerosis; evaluation by IntraVascular UltraSound
More informationComparison of Original and Generic Atorvastatin for the Treatment of Moderate Dyslipidemic Patients
Comparison of Original and Generic Atorvastatin for the Treatment of Moderate Dyslipidemic Patients Cardiology Department, Bangkok Metropolitan Medical College and Vajira Hospital, Bangkok, Thailand Abstract
More informationARMYDA-RECAPTURE (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) trial
ARMYDA-RECAPTURE ( for Reduction of MYocardial Damage during Angioplasty) trial Prospective, multicenter, randomized, double blind trial investigating efficacy of atorvastatin reload in patients on chronic
More informationCardiac CT for Risk Assessment: Do we need to look beyond Coronary Artery Calcification
Cardiac CT for Risk Assessment: Do we need to look beyond Coronary Artery Calcification Matthew Budoff, MD, FACC, FAHA Professor of Medicine Director, Cardiac CT Harbor-UCLA Medical Center, Torrance, CA
More informationNew evidences in heart failure: the GISSI-HF trial. Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy
New evidences in heart failure: the GISSI-HF trial Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy % Improving survival in chronic HF and LV systolic dysfunction: 1 year all-cause mortality 20
More informationTHE LATEST IN CARDIOVASCULAR RISK LIPID MANAGEMENT
THE LATEST IN CARDIOVASCULAR RISK LIPID MANAGEMENT Thomas F. Whayne, Jr, MD, PhD, FACC Professor of Medicine (Cardiology) Gill Heart Institute University of Kentucky April 2016 E-mail: twhayn0@uky.edu
More information